GNRH1 and non-small cell lung carcinoma: Viability inhibition potency of crizotinib*, [d-Lys6(crizotinib*)]–GnRH-I, MJ55*, [d-Lys6(MJ55*)]–GnRH-I, and [d-Lys6]–GnRH-I was investigated in EBC-1 NSCLC cells and human primary skin fibroblast cells by CellTiter-Glo assay (Figure 4A).